KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) EBITDA (2016 - 2025)

West Pharmaceutical Services' EBITDA history spans 17 years, with the latest figure at $156.6 million for Q4 2025.

  • For Q4 2025, EBITDA fell 1.88% year-over-year to $156.6 million; the TTM value through Dec 2025 reached $584.9 million, up 2.63%, while the annual FY2025 figure was $584.9 million, 2.63% up from the prior year.
  • EBITDA for Q4 2025 was $156.6 million at West Pharmaceutical Services, down from $167.6 million in the prior quarter.
  • Across five years, EBITDA topped out at $228.4 million in Q2 2022 and bottomed at $107.0 million in Q1 2025.
  • The 5-year median for EBITDA is $164.4 million (2024), against an average of $165.9 million.
  • The largest annual shift saw EBITDA surged 103.96% in 2021 before it crashed 30.85% in 2024.
  • A 5-year view of EBITDA shows it stood at $184.0 million in 2021, then decreased by 29.51% to $129.7 million in 2022, then rose by 24.06% to $160.9 million in 2023, then dropped by 0.81% to $159.6 million in 2024, then decreased by 1.88% to $156.6 million in 2025.
  • Per Business Quant, the three most recent readings for WST's EBITDA are $156.6 million (Q4 2025), $167.6 million (Q3 2025), and $153.7 million (Q2 2025).